Candel Therapeutics Targets Q4 2026 BLA Submission for Prostate Cancer Drug — Candel Therapeutics, Inc.

Event summary

Candel Therapeutics plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec in Q4 2026 for localized prostate cancer.
Phase 3 clinical trial data published in The Lancet Oncology showed a 39% improvement in disease-free survival with aglatimagene plus radiotherapy.
First trial site activated for the AURORA phase 3 clinical trial evaluating aglatimagene in advanced NSCLC.
Appointed Mark Sims as Chief Commercial Officer to prepare for potential U.S. launch of aglatimagene in 2027.

The big picture

Candel Therapeutics is advancing its lead candidate, aglatimagene besadenovec, toward a potential regulatory approval in localized prostate cancer. The company's strategic focus on commercial readiness and expanding clinical trials into other solid tumors like NSCLC positions it to capitalize on the growing demand for innovative immunotherapies. With a strong cash position expected to last into Q1 2028, Candel is well-positioned to execute its operating plan and potentially launch aglatimagene in the U.S. market if approved.

What we're watching

Regulatory Timeline: Whether the BLA submission in Q4 2026 will meet FDA expectations and lead to a potential approval in 2027.
Commercial Readiness: How effectively Candel Therapeutics can scale its commercial operations with the appointment of Mark Sims as Chief Commercial Officer.
Clinical Trial Progress: The pace at which the AURORA phase 3 trial in NSCLC enrolls patients and generates data to support broader indications for aglatimagene.